AdvisorShares Psychedelics ETF—— (—)Compass Pathways—— (—)Definium Therapeutics—— (—)GH Research—— (—)Helus Pharma—— (—)MIRA Pharmaceuticals—— (—)Neuphoria Therapeutics—— (—)Eli Lilly—— (—)Johnson & Johnson—— (—)AbbVie—— (—)Otsuka Pharmaceutical—— (—)Numinus Wellness—— (—)Optimi Health—— (—)PharmAla Biotech—— (—)Enveric Biosciences—— (—)Incannex Healthcare—— (—)Aurora Cannabis—— (—)Cronos Group—— (—)SNDL—— (—)Bright Minds Biosciences—— (—)PharmaTher Holdings—— (—)IM Cannabis—— (—)MariMed—— (—)Vireo Growth—— (—)

Loading prices

Marijuanamoment

Published November 9, 2026

DEA Boosts Psychedelic Production Quotas For 2027 While Previewing Separate Marijuana ...

Read the full story at Marijuanamoment

The Drug Enforcement Administration (DEA) is moving to dramatically increase the amount of certain psychedelics that can be legally produced in.

Post on X

Share this story

Surfaced by this Google Alert

Psychedelics